» Articles » PMID: 22305969

Metabolomics: a Tool for Early Detection of Toxicological Effects and an Opportunity for Biology Based Grouping of Chemicals-from QSAR to QBAR

Overview
Journal Mutat Res
Publisher Elsevier
Specialty Genetics
Date 2012 Feb 7
PMID 22305969
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

BASF has developed a Metabolomics database (MetaMap(®) Tox) containing approximately 500 data rich chemicals, agrochemicals and drugs. This metabolome-database has been built based upon 28-day studies in rats (adapted to OECD 407 guideline) with blood sampling and metabolic profiling after 7, 14 and 28 days of test substance treatment. Numerous metabolome patterns have been established for different toxicological targets (liver, kidney, thyroid, testes, blood, nervous system and endocrine system) which are specific for different toxicological modes of action. With these patterns early detection of toxicological effects and the underlying mechanism can now be obtained from routine studies. Early recognition of toxicological mode of action will help to develop new compounds with a more favourable toxicological profile and will also help to reduce the number of animal studies necessary to do so. Thus this technology contributes to animal welfare by means of reduction through refinement (2R), but also has potential as a replacement method by analyzing samples from in vitro studies. With respect to the REACH legislation for which a large number of animal studies will need to be performed, one of the most promising methods to reduce the number of animal experiments is grouping of chemicals and read-across to those which are data rich. So far mostly chemical similarity or QSAR models are driving the selection process of chemical grouping. However, "omics" technologies such as metabolomics may help to optimize the chemical grouping process by providing biologically based criteria for toxicological equivalence. "From QSAR to QBAR" (quantitative biological activity relationship).

Citing Articles

Demonstrating the reliability of in vivo metabolomics based chemical grouping: towards best practice.

Viant M, Amstalden E, Athersuch T, Bouhifd M, Camuzeaux S, Crizer D Arch Toxicol. 2024; 98(4):1111-1123.

PMID: 38368582 PMC: 10944399. DOI: 10.1007/s00204-024-03680-y.


Simultaneously discovering the fate and biochemical effects of pharmaceuticals through untargeted metabolomics.

Bowen T, Southam A, Hall A, Weber R, Lloyd G, Macdonald R Nat Commun. 2023; 14(1):4653.

PMID: 37537184 PMC: 10400635. DOI: 10.1038/s41467-023-40333-7.


Derivation of metabolic point of departure using high-throughput in vitro metabolomics: investigating the importance of sampling time points on benchmark concentration values in the HepaRG cell line.

Malinowska J, Palosaari T, Sund J, Carpi D, Weber R, Lloyd G Arch Toxicol. 2023; 97(3):721-735.

PMID: 36683062 PMC: 9968698. DOI: 10.1007/s00204-022-03439-3.


approaches in organ toxicity hazard assessment: Current status and future needs for predicting heart, kidney and lung toxicities.

Bassan A, Alves V, Amberg A, Anger L, Beilke L, Bender A Comput Toxicol. 2022; 20.

PMID: 35721273 PMC: 9205464. DOI: 10.1016/j.comtox.2021.100188.


Plasma fatty acid metabolic profiling coupled with clinical research reveals the risk factors for atherosclerosis development in type 2 diabetes mellitus.

Zhou Q, Ren D, Xiao Y, Yi L, Zhou Z RSC Adv. 2022; 9(62):36162-36170.

PMID: 35540605 PMC: 9074937. DOI: 10.1039/c9ra07634d.